Artivion is a speculative medical-device recovery story trading 53% off its 52-week high with 57.6% upside to the analyst target, but it is GAAP-unprofitable, depends on sole-source suppliers and sits in a confirmed downtrend.
Thesis pillars
- Fcf Positive Despite Gaap Loss→Stable
- Analyst Upside From Drawdown↓Deteriorating
- Sole Source Supplier Concentration↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 18, 2026
Artivion, Inc. (AORT) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Multiple concerning factors at $26.45: Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer.
Artivion manufactures medical devices and processes implantable human tissues for cardiac and vascular surgery, with segments spanning Medical Devices (aortic stent grafts, On-X valves, BioGlue sealant) and Preservation Services. Products are sold globally across North America,... Read more
Sell if holding. Multiple concerning factors at $26.45: Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer. Chart setup: Death cross but MACD improving, RSI 76. Score 5.4/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: speculative.
Recent developments
updated Oct 29, 2026Recent Developments — Artivion, Inc.
Latest news
- NEWS AORT Q3'26 Earnings: revenue estimate is 120.97M USD - TradingView — TradingView Oct 29, 2026 neutral
- NEWS Why Artivion (AORT) Stock Is Trading Up Today - Yahoo Finance — Yahoo Finance Aug 19, 2026 positive
- NEWS Summit Creek Advisors LLC Takes Position in Artivion, Inc. $AORT - MarketBeat — MarketBeat Aug 19, 2026 neutral
- NEWS Artivion (NYSE:AORT) Stock Price Up 5.7% - Still a Buy? - MarketBeat — MarketBeat Aug 18, 2026 positive
- NEWS AORT Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus — GuruFocus Aug 18, 2026 positive
Latest item Oct 29, 2026 · Generated 2026-11-05T11:49:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierEndospan (NEXUS family)10-K Item 1A: 'the NEXUS family of products are solely manufactured by Endospan in Herzliya, Israel'
- HIGHSupplierAMDS sole manufacturer10-K Item 1A: 'The AMDS product is solely manufactured by a supplier in Charlotte, North Carolina'
- HIGHSupplierBioGlue single-supplier delivery devices10-K Item 1A: 'We are significantly dependent on our revenues from BioGlue ... The delivery devices are manufactured by a single supplier, using resin supplied by a different single supplier'
- HIGHSupplierOn-X AAP single-supplier grafts10-K Item 1A: 'We purchase grafts for our On-X AAP from a single supplier'
- MEDIUMProductBioGlue10-K Item 1A: 'BioGlue is a significant source of our revenues'
- MEDIUMProductOn-X products10-K Item 1A: 'On-X products are a significant source of our revenues'
- MEDIUMProductaortic stent grafts10-K Item 1A: 'Aortic stent grafts are a significant source of our revenues'
- MEDIUMProducttissue preservation services10-K Item 1A: 'Tissue preservation services are a significant source of our revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $26.45: Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer. Chart setup: Death cross but MACD improving, RSI 76. Prior stop was $24.60. Score 5.4/10, moderate confidence.
Analyst target: $35.59 (+34.6% upside). Prior stop was $24.60. Stop-loss: $24.60.
Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7).
Artivion, Inc. trades at a P/E of N/A (forward 35.3). TrendMatrix value score: 6.1/10. Verdict: Sell.
15 analysts rate AORT, with a consensus score of 4.3/5. 9 analysts publish price targets averaging $41.
What does Artivion, Inc. do?Artivion manufactures medical devices and processes implantable human tissues for cardiac and vascular surgery, with...
Artivion manufactures medical devices and processes implantable human tissues for cardiac and vascular surgery, with segments spanning Medical Devices (aortic stent grafts, On-X valves, BioGlue sealant) and Preservation Services. Products are sold globally across North America, EMEA, APAC, and LATAM from facilities in Georgia, Texas, and Germany. BioGlue, On-X products, aortic stent grafts, and tissue preservation services are each individually characterized as significant revenue sources.